13C-5-FU breath test current status and future directions: A comprehensive review

Hany H. Ezzeldin, Edward P. Acosta, Lori K. Mattison, Jeanne Fourie, Anil Modak, Robert B Diasio

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Breath tests (BTs) represent a safe non-invasive alternative strategy that could provide valuable diagnostic information in conditions like fat malabsorption, carbohydrate (lactose and fructose) malabsorption, liver dysfunction, impaired gastric emptying, abnormal small bowel transit time, small intestinal bacterial overgrowth and Helicobacter pylori infection. To date, despite the availability of a number of breath tests, only three have gained approval by the FDA for application in a clinical setting (13C-urea breath test for the detection of H. pylori; NO breath test for monitoring asthma and alkane breath test for heart transplant rejection). Unfortunately, none of these tests investigate cancer patients or response to cancer chemotherapy. Several years ago it was realized that the presence of a reliable non-invasive approach could assist in the detection of patients at risk of developing severe life-threatening toxicities prior to the administration of fluoropyrimidines (e.g. 5-FU) or related cancer chemotherapy. 5-FU toxicity results mainly from deficient uracil catabolism. This review discusses the development of a BT that utilizes an orally administered pyrimidine ([2-13C]-uracil) which is metabolized via the same catabolic pathway as 5-FU. This ([2- 13C]-uracil) breath test could provide a valuable addition to the patients' standard of care.

Original languageEnglish (US)
Article number047002
JournalJournal of Breath Research
Volume3
Issue number4
DOIs
StatePublished - 2009

Fingerprint

Breath Tests
Fluorouracil
Uracil
Helicobacter pylori
Lactose Intolerance
Drug Therapy
Neoplasms
Alkanes
Gastric Emptying
Graft Rejection
Helicobacter Infections
Standard of Care
Direction compound
Fructose
Urea
Liver Diseases
Patient Care
Asthma
Fats
Carbohydrates

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

13C-5-FU breath test current status and future directions : A comprehensive review. / Ezzeldin, Hany H.; Acosta, Edward P.; Mattison, Lori K.; Fourie, Jeanne; Modak, Anil; Diasio, Robert B.

In: Journal of Breath Research, Vol. 3, No. 4, 047002, 2009.

Research output: Contribution to journalArticle

Ezzeldin, Hany H. ; Acosta, Edward P. ; Mattison, Lori K. ; Fourie, Jeanne ; Modak, Anil ; Diasio, Robert B. / 13C-5-FU breath test current status and future directions : A comprehensive review. In: Journal of Breath Research. 2009 ; Vol. 3, No. 4.
@article{e4bc794dc08c4e6489fbbb90e6dc81df,
title = "13C-5-FU breath test current status and future directions: A comprehensive review",
abstract = "Breath tests (BTs) represent a safe non-invasive alternative strategy that could provide valuable diagnostic information in conditions like fat malabsorption, carbohydrate (lactose and fructose) malabsorption, liver dysfunction, impaired gastric emptying, abnormal small bowel transit time, small intestinal bacterial overgrowth and Helicobacter pylori infection. To date, despite the availability of a number of breath tests, only three have gained approval by the FDA for application in a clinical setting (13C-urea breath test for the detection of H. pylori; NO breath test for monitoring asthma and alkane breath test for heart transplant rejection). Unfortunately, none of these tests investigate cancer patients or response to cancer chemotherapy. Several years ago it was realized that the presence of a reliable non-invasive approach could assist in the detection of patients at risk of developing severe life-threatening toxicities prior to the administration of fluoropyrimidines (e.g. 5-FU) or related cancer chemotherapy. 5-FU toxicity results mainly from deficient uracil catabolism. This review discusses the development of a BT that utilizes an orally administered pyrimidine ([2-13C]-uracil) which is metabolized via the same catabolic pathway as 5-FU. This ([2- 13C]-uracil) breath test could provide a valuable addition to the patients' standard of care.",
author = "Ezzeldin, {Hany H.} and Acosta, {Edward P.} and Mattison, {Lori K.} and Jeanne Fourie and Anil Modak and Diasio, {Robert B}",
year = "2009",
doi = "10.1088/1752-7155/3/4/047002",
language = "English (US)",
volume = "3",
journal = "Journal of Breath Research",
issn = "1752-7155",
publisher = "IOP Publishing Ltd.",
number = "4",

}

TY - JOUR

T1 - 13C-5-FU breath test current status and future directions

T2 - A comprehensive review

AU - Ezzeldin, Hany H.

AU - Acosta, Edward P.

AU - Mattison, Lori K.

AU - Fourie, Jeanne

AU - Modak, Anil

AU - Diasio, Robert B

PY - 2009

Y1 - 2009

N2 - Breath tests (BTs) represent a safe non-invasive alternative strategy that could provide valuable diagnostic information in conditions like fat malabsorption, carbohydrate (lactose and fructose) malabsorption, liver dysfunction, impaired gastric emptying, abnormal small bowel transit time, small intestinal bacterial overgrowth and Helicobacter pylori infection. To date, despite the availability of a number of breath tests, only three have gained approval by the FDA for application in a clinical setting (13C-urea breath test for the detection of H. pylori; NO breath test for monitoring asthma and alkane breath test for heart transplant rejection). Unfortunately, none of these tests investigate cancer patients or response to cancer chemotherapy. Several years ago it was realized that the presence of a reliable non-invasive approach could assist in the detection of patients at risk of developing severe life-threatening toxicities prior to the administration of fluoropyrimidines (e.g. 5-FU) or related cancer chemotherapy. 5-FU toxicity results mainly from deficient uracil catabolism. This review discusses the development of a BT that utilizes an orally administered pyrimidine ([2-13C]-uracil) which is metabolized via the same catabolic pathway as 5-FU. This ([2- 13C]-uracil) breath test could provide a valuable addition to the patients' standard of care.

AB - Breath tests (BTs) represent a safe non-invasive alternative strategy that could provide valuable diagnostic information in conditions like fat malabsorption, carbohydrate (lactose and fructose) malabsorption, liver dysfunction, impaired gastric emptying, abnormal small bowel transit time, small intestinal bacterial overgrowth and Helicobacter pylori infection. To date, despite the availability of a number of breath tests, only three have gained approval by the FDA for application in a clinical setting (13C-urea breath test for the detection of H. pylori; NO breath test for monitoring asthma and alkane breath test for heart transplant rejection). Unfortunately, none of these tests investigate cancer patients or response to cancer chemotherapy. Several years ago it was realized that the presence of a reliable non-invasive approach could assist in the detection of patients at risk of developing severe life-threatening toxicities prior to the administration of fluoropyrimidines (e.g. 5-FU) or related cancer chemotherapy. 5-FU toxicity results mainly from deficient uracil catabolism. This review discusses the development of a BT that utilizes an orally administered pyrimidine ([2-13C]-uracil) which is metabolized via the same catabolic pathway as 5-FU. This ([2- 13C]-uracil) breath test could provide a valuable addition to the patients' standard of care.

UR - http://www.scopus.com/inward/record.url?scp=72349099452&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=72349099452&partnerID=8YFLogxK

U2 - 10.1088/1752-7155/3/4/047002

DO - 10.1088/1752-7155/3/4/047002

M3 - Article

C2 - 21386199

AN - SCOPUS:72349099452

VL - 3

JO - Journal of Breath Research

JF - Journal of Breath Research

SN - 1752-7155

IS - 4

M1 - 047002

ER -